Research

Breast Trials

PCG – BRE007-12

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

The primary objective of this study is to determine freedom from ipsilateral breast recurrence occurrences in patients receiving partial breast proton radiation therapy limited to the region of the tumor at 3 years.

To find out more about this trial please contact PCG Research Project Manager, Corey Woods at [email protected] or click here:

PCG – BRE008-12

Phase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients with Stage II/III, Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation with Lymph Node Irradiation

The purpose of this study is to look at the rates of acute and long term adverse events of postoperative proton radiotherapy for complex loco-regional irradiation in women with loco-regionally advanced breast cancer. This study specifically includes longitudinal follow up to assess the incidence of cardiac mortality and second malignant neoplasms at 10 and 15 years following proton therapy.

To find out more about this trial please contact PCG Research Project Manager, Corey Woods at [email protected] or click here:

Lung Trials

PCG – LUN005-12

A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using standard chemotherapy in combination with hypofractionated proton radiation therapy. Hypofractionation is a technique that delivers higher daily doses of radiation over a shorter period of time.

To find out more about this trial please contact PCG Research Project Manager, Corey Woods at [email protected] or click here:

Prostate Trials

PCG – GU002-10

A Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation with Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate

This study is for patients who have been staged with low risk prostate cancer. The study is comparing the good and bad effects of 5 treatments (hypo-fractionation) of proton radiation to 44 treatments (standard-fractionation) of proton radiation.

To find out more about this trial please contact PCG Research Project Manager, Corey Woods at [email protected] or click here:

PCG – GU003-10

Phase III Study of Mildly Hypo-fractionated Image Guided Proton Beam Radiation Therapy with or without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate

This study is for patients who have been staged with intermediate risk prostate cancer. In this study all patients will receive a mildly hypo-fractionated dose of radiation (28 treatment days). Patients in group 1 will receive additional androgen deprivation therapy, patients in group 2 will not receive additional treatment.

To find out more about this trial please contact PCG Research Project Manager, Corey Woods at [email protected] or click here:

Registry Study

PCG – REG001-09

Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Proton Therapy

The tracking program allows the collection and analysis of patient information to evaluate the disease process and treatment related outcomes thus defining strengths and weaknesses of our program ultimately leading to better patient care. The Evaluation Tracking Program (ETP) consists of prospective enrollment and collection of information from the date of the ETP approval and patient consent.

To find out more about this trial please contact PCG Research Project Manager, Corey Woods at [email protected] or click here:

Data Use Requests